A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil in Subjects With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-059)
Sponsor: Merck Sharp & Dohme LLC
A PHASE2 clinical study on Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 15 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2022 — Sep 2022 [monthly]
Completed PHASE2
-
Sep 2021 — Jun 2022 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 10 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Feb 2020 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
-
Jul 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
-
May 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.